By Justin Petrone
Affymetrix last week posted a 5.3 percent decline in third-quarter sales, though it said it is seeing "steady adoption" of its next-generation genotyping array products and turned a loss into a profit.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now. Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
The new Riken president outlines some of his plans for the institute.
The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.
An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.
In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.